ConductScience.org, home

Comparison · NCT00728481-4251bb62

Esomeprazole vs Budesonide: Participants With Presence of Esophageal Rings/Furrows at Six Month Endoscopy

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Esomeprazole vs Budesonide: Participants With Presence of Esophageal Rings/Furrows at Six Month Endoscopy. Trial comparisons, record NCT00728481-4251bb62. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00728481-4251bb62

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.6110.3860.797wilson
Risk in group 20.6070.4240.764wilson
Risk difference, group 1 minus group 20.00397-0.270.265newcombe hybrid score
Risk ratio, group 1 over group 21.010.6271.62log
Odds ratio, group 1 over group 21.020.3023.42log
Number needed to treat, for one more participant with the outcome on Esomeprazole than on Budesonide252from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1EsomeprazoleProton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks for subjects with positive 24 hour pH study1118OG000
Group 2Budesonide
Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
1728OG001

Outcome

Type
SECONDARY
Title
Participants With Presence of Esophageal Rings/Furrows at Six Month Endoscopy
Description
Multiple concentric rings or furrows of the esophagus is an endoscopic finding traditionally ascribed to eosinophilic esophagitis.
Time frame
Baseline, 6 months
Population

Source ClinicalTrials.gov

Trial

Title
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
NCT number
NCT00728481
Phases
PHASE2, PHASE3
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Lead sponsor
Mayo Clinic
Results first posted
2012-12-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00728481-4251bb62